A comparison study of in-vivo pharmacokinetic parameters after oral cilnidipine nanocrystals administration in rats.

The purpose of the current research aimed to evaluate the in vivo pharmacokinetics parameters of the formulated cilnidipine nanocrystals (CLND NCs) after oral dosing in comparison to orally CLND dispersion. Cilnidipine is a Ca+2 channel blocker applied to control elevated blood pressure and its vascular prognosis. The solvent-anti-solvent method was utilized to prepare CLND NCs. The bioavailability parameters were measured in male Westar rats (n = 12), and each rat weighed between 200 ±20 grams. Rats were split up into two groups with an equal number in each (n=6). All groups fasted for twelve hours permitting water to be consumed before the trial. Blood samples (a half mL) were withdrawn from the retro-orbital venous plexus at (5, 15, 30, 45 minutes) and (1.0 2.0, 6.0, 8.0, 10.0, 12.0 hours) after receiving. Furthermore, the CLND plasma concentration of rats was calculated using HPLC. Findings showed that the relative bioavailability of CLD NCs was approximately 2.17 folds higher in comparison with the bulk CLND, and the maximum plasma concentration at (CPmax) was also increased. As well, the Tmax of the CLND NCs was less than pure drugs. The Conclusion achieved that overall results suggest that the developed CLND NCs was a proper mean for the promotion rate of dissolution and oral bioavailability of CLND. [ABSTRACT FROM AUTHOR]